News | August 13, 2022
AstraZeneca completes acquisition of TeneoTwo
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The drug will be available in 600 hospitals and 105 DTPs
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The peptide-based vaccine induces a t cell-dependent response
Subscribe To Our Newsletter & Stay Updated
